[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627660":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":43,"responsibleParty":61,"collaborators":25,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":25,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":85,"overallStatus":45,"whyStopped":25,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Primorsky Regional General Hospital #1","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Morphine","ACTIVE_COMPARATOR","Patients after CABG with morphine postoperative analgesia",[13],"Drug: Morphine (+)",{"label":15,"type":16,"description":17,"interventionNames":18},"Tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amide)","EXPERIMENTAL","Patients after CABG with tafalgin postoperative analgesia",[19],"Drug: Tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amide)",[21,26],{"type":22,"name":15,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Postoperative analgesia after CABG with tafalgin",[15],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Morphine (+)","Postoperative analgesia wtih morphine",[9],[31],{"name":32,"affiliation":25,"role":33},"Evgenii Kokarev, PhD","PRINCIPAL_INVESTIGATOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Vladislav Rublev, PhD","CONTACT","+79644530700","dr.rublev.v@gmail.com",{"name":32,"role":37,"phone":41,"phoneExt":25,"email":42},"+79098591131","kokareve@yandex.ru",[44],{"facility":5,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"RECRUITING","Vladivostok","Outside US","690091","Russia","RU",{"type":52,"coordinates":53},"Point",[54,55],131.87353,43.10562,{"lat":55,"lon":54},[58],{"name":59,"role":37,"phone":60,"phoneExt":25,"email":39},"Vladislav Rublev","89644530700",{"type":33,"investigatorFullName":59,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Head of EP, Principal Investigator, MD, PhD","100627660","comparative-analysis-of-analgesic-approaches-in-the-early-period-after-cabg-100627660",false,"NCT07451522","Comparative Analysis of Analgesic Approaches in the Early Period After CABG","Comparative Characteristics of Analgesia Methods in the Early Postoperative Period After Coronary Artery Bypass Grafting (CABG)","CABG-PAIN","Inclusion Criteria:\n\n* ASA score less then 3, Signed inform consent, Absence of preoperative drugs administration that affects patient's perception of pain, No active infection process, BMI index \\>18,5 kg\\\\m2 and \\\u003C 35 kg\u002Fm2, CABG, Age 18-75 years\n\nExclusion Criteria (the presence of at least one is sufficient):\n\n* Failure to meet the inclusion criteria.\n* High severity according to ASA (class IV or higher), which is associated with a high probability of prolonged mechanical ventilation, hemodynamic instability, and inability to use drugs affecting cardiac output and\u002For total peripheral vascular resistance.\n* Contraindications to the use of tafalgin and\u002For morphine in accordance with the approved Summary of Product Characteristics (hypersensitivity to tafalgin, morphine, other opioids, or any excipients).\n* Pregnancy or lactation.\n* Acute or prolonged chronic intoxication with drugs or substances depressing the central nervous system (alcohol, barbiturates, opioid drugs, benzodiazepines).\n* Use of monoamine oxidase inhibitors (MAOIs) or less than 14 days since their discontinuation.\n* Liver cirrhosis, Child-Pugh class C.\n* Acute renal failure requiring renal replacement therapy.\n* Unresected malignant neoplasm.\n* Mesenteric thrombosis or another severe abdominal pain syndrome of unclear etiology at the time of inclusion.\n* Simultaneous participation in another clinical study.\n* Marked CNS depression due to any cause, except for acute poisoning.\n* COPD stage III and\u002For bronchial asthma in the exacerbation phase.\n* Any clinically significant condition, disease, or circumstance in the medical history that, in the opinion of the investigator, precludes participation in the study.\n* Psychiatric, physical, or other conditions preventing adequate assessment of the patient's behavior or proper compliance with the study protocol.\n* Postoperative hemodynamic instability requiring high-dose inotropic and\u002For vasopressor support (epinephrine \\> 0.1 μg\u002Fkg\u002Fmin, dopamine \\> 10 μg\u002Fkg\u002Fmin, norepinephrine \\> 0.2 μg\u002Fkg\u002Fmin) and\u002For mechanical circulatory support.\n* Refusal to participate in the study.","ALL","18 Years","75 Years",{"count":75,"type":76},100,"ESTIMATED","INTERVENTIONAL",[79],"NA","The goal of this clinical trial is to study postoperative analgesia in patients undergoing CABG. And learn if tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid) treats pain not inferiory then morphine. The main questions it aims to answer are:\n\nDoes tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid) lower the VAS score same way as a morphine? What medical problems do participants have when taking tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid)?\n\nParticipants will:\n\nGroup (1)- subcutaneous single dose of morphine 10 mg would be administred based on VAS score \\> 3 during 24 hours after CABG.\n\nExprimental group (2)- subcutaneous single dose of tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid) - 0.4 mg would be administred based on VAS score \\> 3 during 24 hours after CABG.\n\nEfficacy was assessed using the VAS scale decreassion. Hemodynamic parameters and arterial blood gases were also assessed.",[82,83,84],"CAD - Coronary Artery Disease","CABG","Analgesia Assessment",[83,86,9,87,88],"CAD","Tafalgin","VAS","2026-02-28",{"date":91,"type":92},"2026-03-05","ACTUAL",{"date":94,"type":92},"2025-12-01",{"date":96,"type":76},"2026-03-15",{"name":5,"class":6},1]